title: More on melanoma with transdifferentiation.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Panzara
authors.forename: Carmen
authors.initials: C
authors.lastname: Bozic
authors.forename: Alfred W
authors.initials: AW
authors.lastname: Sandrock
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D054338:Cell Transdifferentiation; D006801:Humans; D015994:Incidence; D039441:Integrin alpha4 / Q000276:immunology*; D008545:Melanoma / Q000139:chemically induced*; D015201:Meta-Analysis as Topic; D009103:Multiple Sclerosis / Q000188:drug therapy; D000069442:Natalizumab; D011358:Product Surveillance, Postmarketing; D012306:Risk; D012878:Skin Neoplasms / Q000139:chemically induced*; D019010:Vascular Cell Adhesion Molecule-1 / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D019010:Vascular Cell Adhesion Molecule-1; D039441:Integrin alpha4